Head of Regulatory Affairs and Quality
4 days ago
New York
Pulmovant's first program, mosliciguat, is designed to provide an effective, once-daily, inhaled treatment option for patients with pulmonary hypertension (PH). Mosliciguat is a novel, potential ...